Brief: XBiotech Announces Positive Final Efficacy Results From Phase II Taskin Trial
19/10/2026 14:19
BRIEF-XBiotech Announces Positive Final Efficacy Results From Phase II Taskin Trial Oct 19 (Reuters) - XBiotech Inc XBIT.O:
ANNOUNCES POSITIVE FINAL EFFICACY RESULTS FROM PHASE II TASKIN TRIAL
49 OF 80 PATIENTS (61.3%) IN VILAMAKITUG ARM ALIVE AT 12 MONTHS, SURPASSING EFFICACY THRESHOLD
44 OF 79 PATIENTS (55.7%) IN CONTROL ARM ALIVE AT 12 MONTHS
Source text: ID:nGNE6WNlKS
Further company coverage: XBIT.O
((Reutersbriefs@thomsonreuters.com;))
Recent news on XBiotech
See all newsBrief: XBiotech Announces Positive Final Efficacy Results From Phase II Taskin Trial
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: XBiotech Inc - John Simard To Retire As CEO Of XBiotech - SEC Filing
Brief: Xbiotech Announces Enrollment Completion Of Phase I Clinical Trial For Hutrukin, A Novel Candidate Therapy For Stroke